We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fully Automated Assay Screens Blood for HIV

By LabMedica International staff writers
Posted on 25 Sep 2009
A fully automated blood screening test for human immunodeficiency virus-1 (HIV-1) /HIV-2 can be used by laboratory professionals to screen individual donors of blood and plasma for antibodies to human immunodeficiency virus type 1 Groups M and O (anti-HIV-1) and type 2 (anti-HIV-2). More...
It can also be used as an aid in the diagnosis of HIV-1/HIV-2 infection.

The new HIV assay can run 160 samples per hour, making it possible to test more than 1,200 samples in an eight-hour shift. Speed and efficiency are important to labs because large volumes of blood are screened each year. According to the American Association of Blood Banks (AABB), eight million volunteers donate about 15 million units of whole blood each year in the United States alone. Each donated unit of blood must be tested for infectious diseases including hepatitis, AIDs, and other diseases caused by retroviruses.

The U.S. Food and Drug Administration (FDA) has approved the new assay, which runs on the Abbott Prism and is called the HIV O Plus test. Following the FDA approval Abbott Diagnostics (Abbott park, IL, USA) has a complete panel of hepatitis and retrovirus tests including the following assays: a hepatitis B core test (Abbott Prism HBcore); a hepatitis B surface antigen test (Abbott Prism HBsAg along with Abbott Prism HBsAg Confirmatory); a hepatitis C test (Abbott Prism HCV); and a human T- lymphotropic virus test (Abbott Prism HTLV-I/HTLV-II).

The assay has not been validated for use with pooled specimens and is not intended for use on cord blood specimens.

Abbott offers a broad range of diagnostic instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices, and clinics. The diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility.

Related Links:
American Association of Blood Banks
Abbott Diagnostics



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Pipette Calibration System
Artel PCS®
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.